CAR-T Cell Therapy for Relapsed or Refractory High-Risk Neuroblastoma
1. GD2-CART01 infusion had an overall response of 63% of patients (33% complete response) with a...
Read MoreApr 18, 2023
1. GD2-CART01 infusion had an overall response of 63% of patients (33% complete response) with a...
Read MoreApr 13, 2023
1.The objective response rate was 30.8% with the majority attributing to partial response. 2. Most...
Read MoreApr 12, 2023
1. In this cohort study, physical activity was associated with improved disease-free survival in...
Read MoreApr 11, 2023
1. Programmed death-ligand 1 copy number loss was identified as an independent risk factor for the...
Read MoreApr 10, 2023
1. In this longitudinal cohort study of 30 728 patients with diffuse large-B-cell lymphoma,...
Read MoreApr 7, 2023
1. In this systematic review and meta-analysis, cancer survivors who received reminiscence therapy...
Read MoreApr 7, 2023
1. Adding disulfiram and copper to standard alkylating chemotherapy for glioblastoma (GB) was not...
Read MoreApr 3, 2023
1. The following genes had statistically significant increased odds ratio of gastric cancer;...
Read MoreMar 30, 2023
1. Fewer patients in the hyperfractionation group reported grade 3 or worse late radiation-induced...
Read MoreMar 27, 2023
1. Canadian patients receive subcutaneous administration of medications and/or fluids more...
Read MoreMar 27, 2023
1. Through the reduction in serum estradiol, there was noninferiority between the 3-times-weekly...
Read MoreMar 22, 2023
1. In this prospective cohort study, the adenoma detection rate (ADR) was inversely associated...
Read MoreMar 22, 2023
1. Disease-free survival in the placebo group was 50.7 months and was never reached in the...
Read MoreMar 20, 2023
1. Localized prostate cancer mortality remains similar between groups receiving prostatectomy,...
Read MoreMar 20, 2023
1. There is a 71% lower risk of disease progression or death in the nirogacestat group than in the...
Read MoreMar 20, 2023
1. Patients allocated to the sotorasib group reported increased progression-free survival compared...
Read MoreMar 20, 2023
1. In this phase II randomized clinical trial, treatment of patients with locally advanced...
Read MoreMar 12, 2023
1. Compared to alisertib alone, adding alisertib to fulvestrant did not increase objective tumour...
Read MoreMar 10, 2023
1. In a Danish cohort, maternal genitourinary tract infection during pregnancy was associated with...
Read MoreMar 10, 2023
1. Mandated and available paid-sick-leave resulted in increased colorectal and breast cancer...
Read More